Skip to content
← Full study record

NCT00487539 · MORE INFO

Limitations, agreements, and source contact

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis · Source last updated 2014-02-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
12 months after study ends, Sponsor will be provided with a copy of the materials at least 45 days prior to submission, with details of proposed date, journal or conference name of publication \& it will have 30 days post receipt to send a written request that the publication be delayed on the basis it exposes intellectual property that requires propriety protection but it will be only for 60 days after which Investigator will be free to publish. The participation of Sponsor will be acknowledged.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Janssen Research & Development
phone
215-793-7540
title
Senior Director
Complete source fields
certain Agreement
other Details
12 months after study ends, Sponsor will be provided with a copy of the materials at least 45 days prior to submission, with details of proposed date, journal or conference name of publication \& it will have 30 days post receipt to send a written request that the publication be delayed on the basis it exposes intellectual property that requires propriety protection but it will be only for 60 days after which Investigator will be free to publish. The participation of Sponsor will be acknowledged.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Janssen Research & Development
phone
215-793-7540
title
Senior Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice